QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=AE4F7F7AAFC4068E9F3136CFBA2A254B;jsessionid=081E2E86E96080529C92C4FB5785CA02;jsessionid=E0FE1E794484B452D522E64720EFE3E7;jsessionid=1E54D1A4EE5C9E37F58F32B38180972D;jsessionid=C4EB41C2765ECDA8FF4B8E224D6E928B;jsessionid=FAFB7EF7B4DE345FECA6C5221563D16D;jsessionid=997417F0BC346895B40739B371690467;jsessionid=1456DB476315BF27759811F56252C7A8 (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=AE4F7F7AAFC4068E9F3136CFBA2A254B;jsessionid=081E2E86E96080529C92C4FB5785CA02;jsessionid=E0FE1E794484B452D522E64720EFE3E7;jsessionid=1E54D1A4EE5C9E37F58F32B38180972D;jsessionid=C4EB41C2765ECDA8FF4B8E224D6E928B;jsessionid=FAFB7EF7B4DE345FECA6C5221563D16D;jsessionid=997417F0BC346895B40739B371690467;jsessionid=1456DB476315BF27759811F56252C7A8